Poster presentation scheduled for Tuesday, Might fifth at 12:30 PM CDT
Denver, CO, April 16, 2026 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical firm growing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for focused supply to the terminal ileum and colon, at present introduced that knowledge from its lead program, PALI-2108, has been chosen for poster presentation at Digestive Illness Week® (DDW) 2026, going down Might 2–5, 2026 in Chicago.
The Firm shall be in attendance alongside members of its Scientific Advisory Board (CAB), additional reinforcing its engagement with main specialists in inflammatory bowel illness because it advances PALI-2108 towards the clinic.
Poster Presentation particulars are as follows: Session Sort: Summary PosterSession Title: Mechanisms of IBD TherapeuticsTitle: Intestine-Focused PDE4 Inhibition with PALI-2108 Demonstrates Fast Scientific, Histologic and Biomarker Enchancment in Ulcerative Colitis: Translational Findings from a Section 1 StudySession Date & Time: Might 5, 2026 from 12:30 PM to 1:30 PM CDTLocation: Poster Corridor, Stage 3, Corridor F2 (McCormick Place)
Administration shall be obtainable to take part in one-on-one conferences with certified members of the investor group.
More Read
Digestive Illness Week is a number one discussion board for specialists within the subject of gastroenterology bringing collectively clinicians, researchers, and pharmaceutical leaders to debate the most recent developments in treating digestive ailments. For extra details about Digestive Illness Week please go to the convention web site.
About Palisade Bio
Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”) is a clinical-stage biopharmaceutical firm advancing next-generation oral PDE4 inhibitor prodrugs designed for gut-targeted supply and selective bioactivation within the ileum and colon, with the objective to enhance pharmacology, tolerability and comfort for sufferers with inflammatory and fibrotic ailments. By means of its differentiated prodrug platform and precision pharmacology technique, Palisade Bio is dedicated to remodeling confirmed PDE4 biology into higher, safer oral therapies.
More Read
The Firm’s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed to provoke localized PDE4 inhibition at websites of illness whereas enabling systemic distribution of the lively drug.
Palisade Bio is now advancing in direction of a Section 2 scientific examine in UC designed to judge scientific remission, response and pharmacodynamic biomarkers over 12 weeks, with an extension section assessing upkeep of remission. For extra data, please go to www.palisadebio.com.
Investor Relations Contact
